ImmuCell (NASDAQ:ICCC) Stock Passes Above 200 Day Moving Average – Should You Sell?

ImmuCell Corporation (NASDAQ:ICCC)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $7.91 and traded as high as $11.27. ImmuCell shares last traded at $11.15, with a volume of 24,451 shares.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ICCC shares. Wall Street Zen upgraded shares of ImmuCell to a “strong-buy” rating in a report on Saturday, June 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmuCell in a research report on Thursday, July 2nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

ImmuCell Stock Down 0.5%

The firm has a 50-day moving average of $10.08 and a 200 day moving average of $7.95. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.82 and a quick ratio of 2.60. The stock has a market capitalization of $100.73 million, a price-to-earnings ratio of -185.47 and a beta of 0.56.

ImmuCell (NASDAQ:ICCC) last posted its quarterly earnings results on Thursday, May 14th. The biotechnology company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.16. ImmuCell had a negative return on equity of 1.88% and a negative net margin of 1.82%.The firm had revenue of $10.36 million for the quarter, compared to analyst estimates of $5.40 million.

Insider Buying and Selling

In other ImmuCell news, CEO Boekhorst Paul Francis Oliv Te purchased 8,000 shares of the stock in a transaction on Thursday, June 18th. The shares were purchased at an average price of $9.49 per share, with a total value of $75,920.00. Following the completion of the transaction, the chief executive officer directly owned 17,785 shares in the company, valued at $168,779.65. This represents a 81.76% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.70% of the company’s stock.

Institutional Trading of ImmuCell

A number of hedge funds have recently made changes to their positions in ICCC. Geode Capital Management LLC increased its holdings in shares of ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after acquiring an additional 2,907 shares during the last quarter. Steadtrust LLC lifted its holdings in ImmuCell by 79.1% during the 4th quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock valued at $349,000 after purchasing an additional 25,070 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in ImmuCell by 3.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 1,749 shares during the last quarter. Mesirow Financial Investment Management Inc. boosted its position in ImmuCell by 199.6% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after purchasing an additional 24,303 shares during the period. Finally, Militia Capital Management LLC bought a new position in ImmuCell during the first quarter worth $114,000. 13.47% of the stock is owned by institutional investors and hedge funds.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.